Pozen News

May 1, 2008 - POZEN Inc. announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at Baird's 2008 Growth Stock Conference on Tuesday, May 13, ... via Med Ad News

The companies announced Friday that the FDA had set the finish line for submitting a marketing application for the companies' cholesterol-lowering drug, mipomersen, a little further down the road than the ... via Motley Fool

Here are the biggest percentage gainers and losers in pre-market trading among companies with a market cap between $50 million and $750 million: Biggest percentage gainers: Encore Wire Corp . via All Stories

Bull and Bear of the Week from Zacks.com Charles Rotblut, senior market analyst for Zacks.com, made Pozen his pick for "Bull of the Week," noting that the company just received FDA approval for its migraine ... via MarketWatch

“The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients.”

Main Category: Headache / Migraine Also Included In: Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 21 Apr 2008 - 0:00 PDT printer ... via Medical News Today

The U.S. Food and Drug Administration has approved Pozen Inc.'s Treximet to treat migraines, the agency said Friday on its Web site. via HON

Here are the day's biggest percentage gainers and losers, along with top volume leaders, among companies with a market cap between $100 million and $750 million: Biggest percentage gainers: EnerNOC Inc. via All Stories

“The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients.”

Clinical studies show Treximet provided significantly more patients migraine pain relief compared to sumatriptan 85 mg LONDON, April 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline and POZEN Inc. via Earth Times

Posted Apr 14th 2008 10:10AM by Paul Foster Filed under: Options Pozen closed at $10. POZN's Treximet PDUFA is April 15, 2008. via Blogging Stocks

Shares of Pozen Inc. fell Tuesday on speculation that a federal warning letter issued to GlaxoSmithKline PLC could delay approval of a drug the companies are developing. via Canadian Business Magazine

Posted Tue Feb 26, 04:53 pm ET Posted By: Jason Napodano, CFA Pozen, Inc. announced on February 25, 2008 the company has submitted the findings from a short-term genotoxic study as part of the complete response ... via Zacks Analyst Blog

POZEN Inc. , today announced results for the fourth quarter and year ended December 31, 2007. via Earth Times

“Everybody is holding their breath for a Treximet approval”

Pozen's fourth-quarter loss of $4.2 million beat analysts' expectations, and the Chapel Hill company reported its second annual profit in three years Tuesday. via News Observer

A gauge of consumer confidence in February is expected to dip from the January level, while a measure of inflation is expected to increase. via News Observer

Feb 21, 2008 - POZEN Inc. , today announced that Dr. William R. Kelce, vice president, preclinical and early clinical development, has been appointed adjunct associate professor, Department of Pediatrics, ... via Med Ad News

Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck 's Zocor, which isn't patent-protected anymore. via Fool.com

Feb 14, 2008 - POZEN Inc. announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at Susquehanna Financial Group's Second Annual SIGnificant ... via Med Ad News

“Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.”

RDATE:12022008 New York, NY -- HealthSonix, Inc. ; Exactech, Inc. ; POZEN Inc. ; Protalex, Inc. via TMCnet

FSV Payment Systems Inc., a leading provider of stored value processing and prepaid card solutions, and MiCash Inc., an innovative licensed money transfer business, - 01/17/2008 - 06:00 AM BOSTON-- --Converted ... via Business Wire

A report has been issued yesterday on pharmaceutical company Pozen, Inc. , in which senior pharma industry analyst Jason Napodano, CFA has awarded a Buy rating to the company. via Zacks Analyst Blog